

343 Views | 6 CrossRef citations to date | 78 Altmetric

Perspectives

Convergence of decision rules for value-based pricing of new innovative drugs

Afschin Gandjour

Pages 209-213 | Published online: 18 Oct 2014

Cite this article <https://doi.org/10.1586/14737167.2015.972374>

Check for updates

Sample our
Medicine, Dentistry, Nursing
& Allied Health Journals

>> [Sign in here](#) to start your access to the latest two volumes for 14 days

Full Article | Figures & data | References | Citations | Metrics

Reprints

We Care About Your Privacy

We and our 855 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting "I Accept" enables tracking technologies to support the purposes shown under "we and our partners process data to provide," whereas selecting "Reject All" or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the ["privacy preferences"] link on the bottom of the webpage [or the floating icon on the bottom-left of the webpage, if applicable]. Your choices will have effect within our Website. For more details, refer to our Privacy Policy. [Here](#)

We and our partners process data to provide:

I Accept

Reject All

Show Purpose



Acknowledgements

The author would like to thank three anonymous reviewers for very helpful comments on an earlier draft.

Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Key iss

- G... es have
in... (VBP)
at
- Th... imally
ac
- Th... der a
l as the
- Th... st.
- A... erbid
ea... question.



- In the long term, it is best for VBP countries in Europe to implicitly collude and set cost-effectiveness thresholds at the level of the lowest acceptable VBP country.
- In response, manufacturers might support initiatives for differential pricing according to national income and ability to pay.

Notes

Related research

People also read

Recommended articles

Cited by
6

Cross-national drug price comparisons with economic weights in external reference pricing in Germany >

Jörg Ma
Expert R
Publishe

Historic
Bulgari

Maria V
Expert R
Publ



medicines in

Information for

- Authors
- R&D professionals
- Editors
- Librarians
- Societies

Opportunities

- Reprints and e-prints
- Advertising solutions
- Accelerated publication
- Corporate access solutions

Keep up to date

Register to receive personalised research and resources by email

 Sign me up

- 
- 
- 
- 
- 

Open access

- Overview
- Open journals
- Open Select
- Dove Medical Press
- F1000Research

Help and information

- Help and contact
- Newsroom
- All journals
- Books

Copyright

Accessib

Registered
5 Howick Pl

or & Francis Group
orma business

